Puma Biotechnology licenses alisertib from Takeda; $7M upfront, up to $287.3M in milestones

PUMA BIOTECHNOLOGY, INC.

Entered exclusive global license for alisertib from Takeda; upfront payment of $7 million.
Potential regulatory and commercial milestones up to $287.3 million, plus tiered royalties.
Puma responsible for development, manufacturing, and commercialization globally.
Must use commercially reasonable efforts in US, UK, France, Germany, Italy, Spain, and Japan.
Puma can terminate on 120 days' notice; Takeda may terminate if Puma halts activities for >12 months.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.